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Abstract
The unfortunate story of the matrix metalloproteinase inhibitor
PG116800, which had no effect on the osteoarthritic process but
had unexpected side effects, highlights the following. First, reality
does not always match the theory. Second, cell biology data must
be interpreted within the context of a specific environment. Third,
the specificity of an enzyme inhibitor is always relative. Finally, a
critical evaluation of the benefit/risk ratio of a drug must be
carefully conducted and checked before and after launch. Well
designed post-marketing surveillance is mandatory.
The process leading to the discovery of a new drug has
completely changed during the past few years. Most
therapeutic molecules launched before the 1990s were
discovered by unsophisticated screening tests or by chance,
without any hypothesis as to their mechanism of action.
Studies on mechanism were usually performed after the drug
had appeared on the market, sometimes many years after its
commercialization. The late 20th century saw the beginning
of unparalleled advances in the field of molecular biology that
have turned drug discovery upside down. Drug development
is now based on basic research findings, such as the effects
of over-expression or deletion of genes encoding novel
proteins or enzymes in specific in vitro systems. This potential
target is then tested in vivo in a translational research
process. Clinical trials are then conducted to determine
whether the risk/benefit ratio is better than that for existing
treatments. This approach is, of course, much more attractive
than the previous one because it relies on an hypothesis
rather than chance. The development of anti-tumour necrosis
factor drugs is a good example of this exciting process.
There should have been a similar success story for the anti-
matrix metalloproteinase (MMP) drugs in the treatment of
osteoarthritis (OA). Basic research revealed that the MMPs, a
family of zinc-containing proteinases, are key enzymes in the
breakdown of extracellular matrix. In vitro and in vivo experi-
ments confirmed that this was also true for the cartilage
matrix. These findings led to the paradigm that destructive
arthritis is the result of an imbalance between matrix break-
down and matrix formation in favour of MMP-induced degra-
dation. It was logical, then, that pharmaceutical companies
were tempted to seek MMP inhibitors, based on the hypo-
thesis that these compounds would block matrix breakdown.
The report by Spector and coworkers [1] shows that
biological systems are sometimes much more complex than
predicted. The MMP inhibitor PG-116800 did not modify
matrix structure in OA patients. Also, it had unexpected side
effects on muscle and skeleton; it limited joint mobility, and
caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s
contracture and persistent tendon thickness or nodules. This
unfortunate story is not the only one in the field of anti-arthritic
drugs. Many hoped that bisphosphonates would be disease-
modifying anti-osteoarthritis drugs because many studies
demonstrated that the subchondral bone plays a major role in
the pathophysiology of OA. However, the phase III pivotal trial
to assess the effect of risedronate yielded negative findings
[2]. Fortunately, the drug had no serious side effects, and
trials of other bone-targeted drugs are ongoing. IL-1 receptor
antagonist is another recent example. The receptor antago-
nist of IL-1 had no clinical effect because it did not counter-
act IL-1, which is the main cytokine involved in cartilage
degradation, when it was injected intra-articularly into OA
knees. These unexpected negative results raise several points.
First, reality does not always match the theory. Many
biological pathways remain to be discovered, although they
may be critical because they interact with a potential drug
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target, making the drug ineffective or producing unexpected
side effects. The infliximab trial for the treatment of heart
failure is a bizarre example [3]. Although the theory and some
experimental data indicated that tumour necrosis factor-α
played a major role in the development of heart failure,
infliximab not only had no effect but made the disease worse,
and so heart failure is now an absolute contraindication for
use of this drug.
Second, cell biology data must be interpreted within the
context of a specific environment, which could differ dramati-
cally from one person to another. Better interactions between
specialties must be encouraged in order to share results on
the same pathway but in different contexts. For example,
MMPs can be deleterious in some diseases, such as OA, but
they may protect the body in others [4]. A systems biology
approach could help to limit such surprises [5].
Third, the specificity of an enzyme inhibitor is always relative.
It depends on many factors such as cell type, concentration
and of course the target itself. A broad MMP inhibitor is
unlikely to have the same effect as a MMP-3 inhibitor, or a
p38-mitogen activated protein kinase (MAPK) inhibitor the
same as a γ-p38-MAPK inhibitor.
Finally, although the enthusiasm of a pharmaceutical com-
pany that is close to launching a potential blockbuster is
understandable, a critical evaluation of the drug’s best
benefit/risk ratio must be carefully conducted. It should be
checked before and after launch, because unexpected side
effects may occur once the drug is used in the real world.
Well designed post-marketing surveillance is mandatory.
Although developing a disease-modifying anti-osteoarthritic
drug that delays joint breakdown in OA appears Utopian, like
the quest for the Holy Grail, it is worthwhile. The dramatic
ageing of the population and the increase in obesity in
developed countries will prove extremely costly both
economically and in terms of quality of life. We should keep in
mind that behind all of the revolutionary drugs presently on
the market is a long history of failure. If we continue to
develop and test hypotheses, then one day we will find the
Holy Grail!
Competing interests
FB is, or has been a consultant for the following companies in
the past 5 years: Pfizer, Novartis, UCB, Nicox, CombinatorX,
Expanscience, AstraZeneca, Takeda, Negma. FB is a member
of the data safety monitoring board for Nicox.
References
1. Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon
R, Beary J, Aronstein WS, Spector TD: Development of
musculoskeletal toxicity without clear benefit after adminis-
tration of PG 116800, a matrix metalloproteinase inhibitor, to
patients with knee osteoarthritis: a randomized, 12 month,
double-blind, placebo-controlled study. Arthritis Res Ther
2007, 9:R109.
2. Bingham CO, Buckland-Wright JC, Garnero P, Cohen SB,
Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Ray-
nauld JP, et al.: Risedronate decreases biochemical markers of
cartilage degradation but does not decrease symptoms or
slow radiographic progression in patients with medial com-
partment osteoarthritis of the knee: results of the two-year
multinational knee osteoarthritis structural arthritis study.
Arthritis Rheum 2006, 54:3494-3507.
3. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-
TNF Therapy Against Congestive Heart Failure Investigators: Ran-
domized, double-blind, placebo-controlled, pilot trial of
infliximab, a chimeric monoclonal antibody to tumor necrosis
factor-alpha, in patients with moderate-to-severe heart
failure: results of the anti-TNF Therapy Against Congestive
Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
4. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases
and the regulation of tissue remodelling. Nat Rev Mol Cell Biol
2007, 8:221-233.
5. Pitluk Z, Khalil I: Achieving confidence in mechanism for drug
discovery and development. Drug Discov Today 2007, 12:924-
930.